References
- Fletcher C, Peto R, Tinker C, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. London: Oxford University Press; 1976.
- Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977 Jun 25; 1(6077):1645–1648.
- Burrows B, Knudson RJ, Camilli AE, Lyle SK, Lebowitz MD. The “horse-racing effect” and predicting decline in forced expiratory volume in one second from screening spirometry. Am Rev Respir Dis 1987 Apr; 135(4):788–793.
- Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011 Sep 29; 365(13):1184–1192.
- Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 Aug 15; 178(4):332–338.
- Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 Oct 9; 359(15):1543–1554.
- Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis 2012; 7:95–99.
- Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, The Danish randomized lung cancer CT screening trial–overall design and results of the prevalence round. J Thorac Oncol 2009 May; 4(5):608–614.
- Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993 Mar; 16:5–40.
- Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Interpretative strategies for lung function tests. Eur Respir J 2005 Nov; 26(5):948–968.
- Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013 Feb 15; 187(4):347–365.
- Lee PN, Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med 2010; 8:84.
- Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012 Jun 15; 185(12):1301–1306.
- Mohamed Hoesein FA, Zanen P, Boezen HM, Groen HJ, van GB, de Jong PA, Lung function decline in heavy male smokers relates to baseline airflow obstruction severity. CHEST 2012 Dec; 142(6):1530–8.
- The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998 Jul; 158(1):49–59.
- Wang ML, Avashia BH, Petsonk EL. Interpreting periodic lung function tests in individuals: the relationship between 1- to 5-year and long-term FEV1 changes. CHEST 2006 Aug; 130(2):493–499.
- Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004 Jun 24; 350(26):2645–2653.
- Burrows B. An overview of obstructive lung diseases. Med Clin North Am 1981 May; 65(3):455–471.
- Hestbech MS, Siersma V, Dirksen A, Pedersen JH, Brodersen J. Participation bias in a randomised trial of screening for lung cancer. Lung Cancer 2011 Sep; 73(3):325–331.